Related Experiment Videos
Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes
John Dupré1, Margaret T Behme, Thomas J McDonald
1Robarts Research Institute, P.O. Box 5015, 100 Perth Drive, London, Ontario N6A 5K8 Canada. john.dupre@lhsc.on.ca
The Journal of Clinical Endocrinology and Metabolism
|July 9, 2004
Summary
Exendin-4, a truncated glucagon-like peptide 1 (tGLP-1) agonist, significantly reduced blood glucose excursions in type 1 diabetes patients. This peptide normalized post-meal glycemia by delaying gastric emptying and suppressing glucagon without affecting insulin levels.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Exendin-4 is a peptide activating the truncated glucagon-like peptide 1 (tGLP-1) receptor.
- Exendin-4 and tGLP-1 lower blood glucose by stimulating insulin, inhibiting glucagon, and delaying gastric emptying.
Purpose of the Study:
- To evaluate the efficacy of exendin-4 in managing postprandial glycemic excursions in type 1 diabetes.
- To determine a safe and effective dose and administration timing for exendin-4.
Main Methods:
- A dose-ranging study of subcutaneous exendin-4 was conducted in volunteers with type 1 diabetes.
- Exendin-4 was administered before breakfast alongside standard insulin therapy.
- Acetaminophen was used to measure gastric emptying rates.
Main Results:
- Exendin-4 administration reduced mean plasma glucose excursion by 90% post-breakfast, normalizing levels.
- A significant reduction in plasma pancreatic polypeptide, glucagon, and acetaminophen was observed.
- Exendin-4 did not affect endogenous or exogenous insulin levels.
Conclusions:
- Exendin-4 normalizes postprandial glycemia in type 1 diabetes by delaying gastric emptying and suppressing glucagon secretion.
- tGLP-1 agonists show therapeutic potential as adjuncts to insulin therapy in C-peptide-negative type 1 diabetes.